Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
1998-02-10
2010-12-07
Anderson, James D (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S312000, C424S641000
Reexamination Certificate
active
07846919
ABSTRACT:
Oxinates including 8-hydroxyquinoline and a heavy metal are topically applied to epidermal lesions for therapeutic effect. The zinc oxinate compositions are shown to be therapeutically effective against The therapeutic composition demonstrates selective toxicity with a therapeutic index of one-hundred percent on human lung cancer, breast cancer, melanoma, venereal warts, male veruoca warts, lesions produced by human papilloma virus, basal cell carcinoma, solar keratosis, and Kaposi's sarcoma. In veterinary applications where dogs, cats, and horses are the patients, the composition shows a one-hundred percent therapeutic index with selective toxicity against eye cancer, sarcoids, sarcoma, malignant melanoma, rectal adenoma, histiocytoma, and sebaceous adenoma.
REFERENCES:
patent: 3637772 (1972-01-01), Klaui et al.
patent: 4469702 (1984-09-01), Schulte
patent: 4766113 (1988-08-01), West et al.
patent: 4780320 (1988-10-01), Baker
patent: 4868172 (1989-09-01), Sebestyen et al.
patent: 5536502 (1996-07-01), Mulder
patent: 5605700 (1997-02-01), DeGregorio et al.
patent: 5684169 (1997-11-01), Hamada et al.
patent: 5817675 (1998-10-01), Whitefield
patent: 6124374 (2000-09-01), Kolias et al.
patent: 6476014 (2002-11-01), Jordan et al.
patent: 6774124 (2004-08-01), Jordan et al.
patent: 199925956 (2003-04-01), None
patent: 0506207 (1985-03-01), None
patent: 0 506 207 (1992-09-01), None
patent: 0506207 (1992-09-01), None
patent: 0634170 (2004-06-01), None
patent: 1215676 (1970-12-01), None
patent: 2 189 144 (1987-10-01), None
patent: WO 88/03805 (1988-06-01), None
patent: 95/03032 (1995-02-01), None
patent: WO99/39721 (1999-08-01), None
Kazimierczak, W. and Maslinski, C. Histamine Release from Mast Cells by Compound 48/80. The Membrane Action of Zinc. Agents and Actions, vol. 4/5 (1974), p. 320-323.
The Merck Index 12th Edition, 1996, Merck & Co., publ., p. 832 (Entry 4890).
Cosmetic Ingredient Review; Ingredient Publication Status, Jun. 24, 1994; 24 pages.
Selective Toxicity by Adrien Albert; 1965; pp. 334-391.
Specifications 6092H; 8-Hydroxyquinoline; 8-Quinolinol; Oxine by Karl Fischer (1 page).
Nordenberg et al., “Anti-proliferative Effects and Phenotypic Alterations Induced by 8-hydroxyquinoline in Melanoma Cell Lines,” Eur J. Cancer (Great Brintain), vol. 26 (No. 8), p. 905-907.
Kazimierczak, W. & Maslinski, C. Histamine Release From Mast Cells by Compound 48/80. The Membrane Action of Zinc. Agents and Actions, vol. 4/5 (1974), p. 320-323.
Cosmetic Ingredient Review; Ingredient Publication Status, Jun. 24, 1994; 24 pages.
Albert, A.; Selective Toxicity; 1965; pp. 334-391.
Specifications 6092H; 8-Hydroxyquinoline; Oxine by Karl Fischer (1 page); undated.
Related U.S. Appl. No. 10/247.526; Notice of Allowability; Dec. 2, 2003.
Related U.S. Appl. No. 10/247,526; Preliminary Amendment; Dec. 19, 2002.
Related U.S. Appl. No. 11/434,613; Office Action Mailed Aug. 30, 2007.
Related U.S. Appl. No. 10/247,161; Preliminary Amendment filed Dec. 9, 2002.
Related U.S. Appl. No. 10/247,161; Notice of Allowability; Dec. 27, 2005.
NZ506367 Dermex Pharmaceticals; Abstract only; Mar. 28, 2003.
DE69935037D Dermex Pharmaceuticals; Abstract only; Mar. 22, 2007.
Related U.S. Appl. No. 10/247,161; Office Action mailed Dec. 19, 2003.
Related U.S. Appl. No. 10/247,161; Response to Office Action mailed Dec. 19, 2003.
Related U.S. Appl. No. 10/247,161; Office Action mailed Sep. 23, 2004.
Related U.S. Appl. No. 10/247,161; Response to Office Action mailed Sep. 23, 2004.
Related U.S. Appl. No. 10/247,161; Office Action mailed Apr. 21, 2005.
Related U.S. Appl. No. 10/247,161; Response to Office Action mailed Apr. 21, 2005.
Related U.S. Appl. No. 09/601,304; Office Action mailed Oct. 24, 2001.
Related U.S. Appl. No. 09/601,304; Response to Office Action mailed Apr. 24, 2002.
Related U.S. Appl. No. 09/601,304; Notice of Allowance mailed Jun. 18, 2002.
Related U.S. Appl. No. 09/601,304; Response to Notice of Allowance mailed Sep. 18, 2002.
Related U.S. Appl. No. 09/601,304; Response to the Amendment of Notice of Allowance mailed Oct. 3, 2002.
Office Action dated Jun. 23, 2010 issued in related U.S. Appl. No. 11/434,613, 10 pages.
Hanson Carl C.
Jordan Russel T.
Potestio Frank S.
Anderson James D
Dermex Pharmaceuticals, LLC
Lathrop & Gage LLP
LandOfFree
Chelated 8-hydroxyquinoline and use thereof in a method of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chelated 8-hydroxyquinoline and use thereof in a method of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chelated 8-hydroxyquinoline and use thereof in a method of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4225156